NVO and LLY Related Headlines
Go Back- Oral GLP-1 obesity drugs see rapid early adoption, Bernstein survey shows
- Pfizer targets obesity market with monthly weight-loss injection data
- Morgan Stanley on Eli Lilly (LLY): 'We see ~7% upside to '26 M+Z ests'
- TD Cowen raises global GLP-1 sales forecast to $150B by 2030
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- FDA Commissioner Marty Makary to step down - Politico
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
- The Next Generation of the GLP-1 Revolution Is Already Underway
- Biotech’s Next Wave May Already be in Motion
- Novo Nordisk reports Q1 earnings on Wednesday: Analysts flag key focus topics
- Why Eli Lilly stock is down 3% today: FDA adverse event data explained
- Novo Nordisk rebrands diabetes tablet as Ozempic in US
- Lilly's Strong GLP-1 Results Signal Robust Market Growth for Novo Nordisk says Barclays
- FDA proposes to exclude semaglutide, tirzepatide from compounding list
- Morgan Stanley Comments on Eli Lilly (LLY) Amid Premarket Volatility
- Hims & Hers expands platform to include Eli Lilly weight loss medications
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- Morgan Stanley Comments Eli Lilly (LLY) and Medicare GLP-1 Obesity Coverage
- Eli Lilly and Novo Nordisk shares fall as CVS opts out of Medicare obesity drug coverage
- CVS Health Opts Out Of Medicare Obesity Drug Coverage Model
- Walmart expands weight management services with virtual care platform
- Novo Nordisk says Wegovy pill shows greater weight loss than Lilly rival
- Wall Street sees multi-billion dollar debut for Lilly's obesity pill despite Novo lead
- Wolfe: 'We're observing some reports of GLP-1 users refreshing their wardrobes as weight loss progresses'
- Should you buy the dip in Novo Nordisk stock? Wall Street analyst answers
- India's Eris Lifesciences launches generic semaglutide at $13.8 per month
- Leerink on Structure Therapeutics (GPCR): 'Oral GLP-1 Achieves Best-In-Class Weight Loss'
- TD Cowen: 'Wegovy Injection may be declining'
- FDA issues 30 warning letters to telehealth firms over GLP-1 claims
- BofA on Eli Lilly (LLY): 'Novo’s GLP-1 price update unlikely to ‘rock the boat’'
- Eli Lilly falls 2% on Novo Nordisk price cut plans
- Novo Nordisk to halve US list price of Wegovy from 2027
- Novo To Cut Ozempic, Wegovy's US List Prices By Up To 50% - WSJ
- Novo Nordisk To Cut Ozempic List Price By 34% - WSJ
- Novo Nordisk selloff continues as stock gets hit with rating downgrades
- Novo Nordisk's CagriSema fails to match tirzepatide in obesity trial
- Novo Nordisk (NVO) -13% after 'worst case' REDEFINE-4 readout; LLY +4%
- Novo Nordisk's CagriSema trial deals blow in obesity drug battle with Eli Lilly
- Hims and Hers (HIMS) PT Lowered to $20 at Leerink Partners
- Novo Nordisk jumps, Hims shares plummet after pulling $49 weight-loss pill
- FDA moves to restrict copycat GLP-1 weight loss drugs
- TD Cowen Reiterates Hold Rating on Hims and Hers (HIMS)
- Truist: 'Defending Lilly: LLY strong position helps guard their share in a crowded GLP-1 landscape'
- Leerink: 'there is no reason why HIMS shouldn't evaluate these launches for every subsequent weight loss product'
- Wolfe Research on Eli Lilly (LLY): 'we question the legality of HIMS' ability to market an oral semaglutide'
- Wells Fargo on Eli Lilly (LLY): 'Compounders Strike Again, but We See Little Risk to Near-Term Growth'
- Hims stock surges as Wegovy pill copy offered at $49, Novo shares fall
- Novo Nordisk shares plunge amid lower 2026 sales outlook
- Eli Lilly & Co. (LLY) sees volatility amid Novo's warning
- Walmart raises pharmacy technician wages as it expands healthcare services
- Novo's Wegovy pill makes encouraging start in weight-loss race vs Lilly
- Novo Nordisk's oral Wegovy reaches 3,071 prescriptions in first four days
- Novo Nordisk CEO warns of international competition headwinds, cites Lilly
- Novo Nordisk (NVO) EVP for product and portfolio strategy: market for oral weight-loss drugs versus injectables bigger than originally thought
- Less than two years after stopping obesity drugs, weight and health issues return, study finds
- Here's the list of top biotech stocks to own for 2026
- Trump to announce prescription drug price agreements
- BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
- BofA Comments on GLP-1s and Potential Pressure Ahead
- Hims stock falls after lawmakers propose GLP-1 compounding restrictions
- What comes next for Eli Lilly (LLY) stock after $1T valuation?
- Bernstein on IRA pricing: $245 really is the floor
- Bernstein on Novo's Alzheimer's miss: 'Don't expect Lilly to stay quiet'
- Lilly, Novo Nordisk back direct-to-employer programs to expand access to weight-loss drugs
- KeyBanc: White House GLP-1 Deals Boost Growth Potential for Key Suppliers
- Novo Nordisk cuts cash prices for Wegovy and Ozempic to $199 monthly
- Mangoceuticals clarifies GLP-1 weight-management program launch
- Lilly and Novo Nordisk say no affiliation with Mangoceuticals (MGRX)
- Novo shares fall after weight-loss drug price deal
- Trump administration reaches GLP-1 drug pricing deals with Eli Lilly and Novo Nordisk - White House
- Trump announcement on weight loss drugs scheduled for 11 A.M. Thursday; price to drop under $150/mo - CBS
- Trump admin talking to Lilly and Novo Nordisk to offer weight-loss drugs at reduced prices via TrumpRx - WSJ
- Lilly and Novo near White House deal on obesity drug prices - Endpoints News
- Novo Nordisk, Eli Lilly fall after Trump comments on weight loss drug pricing
- Eli Lilly Shares Fall 2.7%, Novo Drops 2.8%; Trump: Ozempic, Fatloss Drug Prices To Come Down 'pretty Fast'
- M. Stanley cuts Novo Nordisk to Underweight on ’tough path ahead’, shares slip
- Novo Nordisk: Diabetes and obesity GLP-1 portfolio still attractive says Bernstein
- UBS slashes global GLP-1 sales estimate for 2030 on softer outlook
- Walmart (WMT) Adds Home Delivery for Ozempic, Other Refrigerated Drugs - Bloomberg
- Trump: tariffs will get countries to agree to drug pricing plan
- BMO Capital on Novo Nordisk (NVO): 'still give the competitive edge to Lilly following this week'
- U.S. FDA sends drug advertising warning letters to Lilly, Novo, Hims
- How are GLP-1 drugs changing U.S. grocery behavior?
- Novo Nordisk's Wegovy may quiet thoughts about food, study shows; shares up
- Novo Nordisk (NVO) stock: Barclays breaks down key investor questions and debates
- Hims&Hers gains after court rejects Eli Lilly’s case against Willow
- LLY obesity data seen as small sentiment hit for NVO, no major change—Barclays
- Truist Securities Reiterates Buy Rating on Viking Therapeutic (VKTX)
- Novo Nordisk, Eli Lilly rise after Viking obesity trial data
- What to do with Novo Nordisk shares after recent volatility? Barclays explains
- Morgan Stanley Reiterates Overweight Rating on Eli Lilly (LLY)
- Novo shares rise for second day after Lilly obesity pills trails Wegovy in trial
- Eli Lilly shares slip 7% premarket as weight-loss pill study overshadows earnings
- BofA Securities Reiterates Neutral Rating on Novo Nordisk (NOVOB:DC) (NVO)
- Novo Nordisk shares jump as Eli Lilly obesity pill disappoints
- Novo Nordisk (NVO) stock: Where next after profit warning?
- Eli Lilly stock rises, Novo Nordisk shares jump on potential Medicare coverage
- Trump admin to pilot coverage of weight‑loss drugs under Medicare and Medicaid - WaPo
- Hims & Hers (HIMS) reportedly makes statement on congressional letter to FDA
- Hims & Hers Health, Inc. (NYSE: HIMS) Falls, Group Of 81 Bipartisan Lawmakers Sign Letter On Glp-1 Action
- Morgan Stanley on Compounder Lawsuits: 'experts think the courts would likely refuse to dismiss the case and that it could take 2-3 years to resolve'
- Chardan Comments on iBio, Inc. (IBIO)
- GLP-1s Should Be First Line To Prevent Heart Disease, Acc Says - Bloomberg
NVO and LLY Related Press Releases
Go Back- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
- The Next Generation of the GLP-1 Revolution Is Already Underway
- Biotech’s Next Wave May Already be in Motion
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
